Alpha 2.0
Login Register
» Authors » Masanori Sugimoto

Masanori Sugimoto

Explore the profile of Masanori Sugimoto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 167
Followers 0
Related Specialties
Pharmacology
Dermatology
Endocrinology
Top 10 Co-Authors
Nobuko Futaki
Iwao Arai
Shiro Nakaike
Yuki Hashimoto
Yusuke Honma
Takanobu Sakurai
Tomoyuki Inoue
Akiko Takaoka
Shinsuke Kaku
Yoshihisa Toda
Published In
Eur J Pharmacol
Exp Dermatol
Drug Dev Res
Bone
Mol Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
A Family with Craniofrontonasal Syndrome: The First Report of Familial Cases of Craniofrontonasal Syndrome with Bilateral Cleft Lip and Palate
Inoue Y, Sakamoto Y, Sugimoto M, Inagaki H, Boda H, Miyata M, et al.
Cleft Palate Craniofac J . 2017 Feb; 55(7):1026-1029. PMID: 28140668
Craniofrontonasal syndrome (CFNS) is a very rare genetic disorder, the common physical malformations of which include coronal synostosis, widely spaced eyes, clefting of the nasal tip, and various skeletal anomalies....
2.
Topical Anti-Inflammatory and Analgesic Effects of Multiple Applications of S(+)-Flurbiprofen Plaster (SFPP) in a Rat Adjuvant-Induced Arthritis Model
Sugimoto M, Toda Y, Hori M, Mitani A, Ichihara T, Sekine S, et al.
Drug Dev Res . 2016 Jun; 77(4):206-11. PMID: 27241582
Preclinical Research The aim of this study was to evaluate the efficacy of multiple applications of S(+)-flurbiprofen plaster (SFPP), a novel Nonsteroidal anti-inflammatory drug (NSAID) patch, for the alleviation of...
3.
Analgesic Effect of the Newly Developed S(+)-Flurbiprofen Plaster on Inflammatory Pain in a Rat Adjuvant-Induced Arthritis Model
Sugimoto M, Toda Y, Hori M, Mitani A, Ichihara T, Sekine S, et al.
Drug Dev Res . 2016 Jan; 77(1):20-8. PMID: 26763139
Preclinical Research This article describes the properties of a novel topical NSAID (Nonsteroidal anti-inflammatory drug) patch, SFPP (S(+)-flurbiprofen plaster), containing the potent cyclooxygenase (COX) inhibitor, S(+)-flurbiprofen (SFP). The present studies...
4.
Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats
Sakai S, Takeda S, Sugimoto M, Shimizu M, Shimonaka Y, Yogo K, et al.
Bone . 2015 Aug; 81:449-458. PMID: 26281770
Bisphosphonates are widely used in the treatment of osteoporosis and contribute to the reduction of bone fractures. Ibandronate (IBN) is a highly potent, nitrogen-containing bisphosphonate, which is administered orally or...
5.
Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate
Sugimoto M, Futaki N, Harada M, Kaku S
Bone . 2012 Oct; 52(1):181-8. PMID: 23041510
Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25 (OH) 2D3, inhibits bone resorption more potently than alfacalcidol (ALF) while maintaining osteoblastic function in an ovariectomized (OVX) osteoporosis rat model. Alendronate (ALN),...
6.
Itch-associated scratching contributes to the development of dermatitis and hyperimmunoglobulinaemia E in NC/Nga mice
Hashimoto Y, Takaoka A, Sugimoto M, Honma Y, Sakurai T, Futaki N, et al.
Exp Dermatol . 2011 Jul; 20(10):820-5. PMID: 21771100
Atopic dermatitis (AD) is related to immunoglobulin E (IgE) production, and a type-1 and type-2 helper T cell (Th1/Th2) imbalance has been hypothesized as the aetiology. While itching and scratching...
7.
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation
Futaki N, Harada M, Sugimoto M, Hashimoto Y, Honma Y, Arai I, et al.
J Pharm Pharmacol . 2009 May; 61(5):607-14. PMID: 19405999
Objectives: Lornoxicam is a non-selective cyclooxygenase inhibitor that exhibits strong analgesic and anti-inflammatory effects but a weak antipyretic effect in rat models. Our aim was to investigate the mechanism of...
8.
Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA
Inoue T, Sugimoto M, Sakurai T, Saito R, Futaki N, Hashimoto Y, et al.
J Gene Med . 2007 Aug; 9(11):994-1001. PMID: 17703497
Background: RNA interference (RNAi) is rapidly becoming a major tool that is revolutionizing research in the bioscience and biomedical fields. To apply the RNAi technique in vivo, it is crucial...
9.
Role of scratch-induced cutaneous prostaglandin D production on atopic-like scratching behaviour in mice
Takaoka A, Arai I, Sugimoto M, Futaki N, Sakurai T, Honma Y, et al.
Exp Dermatol . 2007 Mar; 16(4):331-9. PMID: 17359340
NC/Nga mice are known to develop scratching dermatitis akin to atopic dermatitis, under conventional (Conv), but not under the specific-pathogen-free (SPF) condition. In this study, we examined the effects of...
10.
The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice
Sugimoto M, Arai I, Futaki N, Hashimoto Y, Sakurai T, Honma Y, et al.
Eur J Pharmacol . 2007 Mar; 564(1-3):196-203. PMID: 17328887
TS-022 is a prostanoid DP(1) receptor agonist, originally developed as a novel anti-pruritic drug for atopic dermatitis. The drug has been shown to suppress scratching and improve the skin inflammation...